Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, Topics Jun 21 | 2023FDA Places Clinical Hold on Arcellx’s Pivotal Ph2 iMMagine-1 Trial in ≥4L MM; How Could the Hold Affect CART-ddBCMA’s Development Plans?Access Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jun 20 | 2023Impressive Results for Breyanzi in ≥3L FL and ≥3L MCL; MB-106 Demonstrates Excellent Efficacy and Safety in R/R FLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, Topics Jun 19 | 2023Could Abecma Receive a CHMP Positive Opinion This Week? Carvykti Starts EMA Assessment in ≥2L MM; June’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, CAR-T Jun 15 | 20232Seventy Bio’s SC-DARIC-33 Program PausedAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jun 13 | 2023GC012F Demonstrates a Promising Profile in ≥3L DLBCL Patients; ALYCANTE Trial Confirms Yescarta’s Excellent Efficacy in TI 2L LBCL Patients; NKX019 Shows Potential in NHL Patients; EHA 2023 Analysis 3Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 12 | 2023Promising Efficacy Data from BMS’s GPRC5D CAR-T in ≥4L MM; Abecma Demonstrates Superiority Vs SOC in ≥3L MM Across All High-Risk Subgroups; Preliminary Clinical Data from Innovent’s P329G-CAR-T in ≥4L MM; EHA 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CD19, CD22 Jun 11 | 2023Promising Preliminary GC007g Efficacy Data in B-ALL Patients that Relapsed Post-Allo-HSCT; Prior CD19-Targeting Treatments Could Affect Tecartus Efficacy in R/R ALL; UCART22 Shows 50% CR in r/r B-ALL Patients Failing Previous CD19 CAR-T Therapy; EHA 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 08 | 2023IASO, AbClon, Parasol and Affyimmune Present Promising Results of Their New Cell Therapies in Hematological and Solid Tumor Indications; ASCO 2023 Analysis 6Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 07 | 2023Analysis of Breyanzi in CLL/SLL Demonstrates Long Survival in Patients Achieving CR; Yescarta Reduces Risk of Death in 2L LBCL; Tecartus’s RW Study Shows Improved Results when Compared with ZUMA-2; ASCO 2023 Analysis 5Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 06 | 2023Carvykti’s sBLA Application Submitted to the FDA after Outperforming the SOC on CARTITUDE-4 Trial in ≥2L MM; Longer-term Follow-up Data for CARTITUDE-1 and LEGEND-2 Trials; ASCO 2023 Analysis 4Access Free BlastFree
Posted in: Autologous, CAR-T, TCR Jun 05 | 2023Adaptimmune Reports Interim OS Data from SPEARHEAD-1 trial; Automatically Manufactured BNT211 Corroborates Initial Promising Efficacy Results in Solid tumors; Promising Initial Clinical Results of CT0180 in HCC; ASCO 2023 Analysis 3Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 05 | 2023Rapid CAR-T Manufacturing Platforms Show Promise in R/R MM; Novartis and Gracell Present New Ph1 Data for PHE885 and GC012F; ASCO 2023 Analysis 2Access Free BlastFree
Posted in: Autologous, CAR-T, CD19, Topics Jun 03 | 2023Obe-cel Demonstrates Best-In-Class Safety Profile in R/R B-ALL; Autolus Presents Positive Ph2 Results; ASCO 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, CAR-T, CD19, Topics Jun 03 | 2023Adaptimmune and TCR2 Tx Complete Strategic CombinationAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Jun 01 | 2023Azer-cel’s Potential Ph2 Trial in CAR-T-Relapsed DLBCL Patients; Clinical Updates for Azer-cel and PBCAR19B; Precision’s Mid-Year 2023 EventAccess Free Blast
Free
Posted in: Autologous, BCMA May 26 | 2023Carvykti’s Type II Variation Application Submitted to the EMA; Carvykti’s Submission to the FDA Planned; Could Carvykti be First Approved for ≥2L MM in Europe Ahead of the US?Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 May 23 | 2023Encouraging Preclinical Data from ARI-0003, a New Academic Dual CAR-T for NHL; Can ARI-0003 Repeat the Success of ARI-0001? MiNK Tx Presented Preclinical Data of MiNK-215 in NSCLC; ASCGT 2023 Analysis 3Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, Topics May 23 | 2023No Cell Therapy-Related Updates in May’s CHMP Agenda; Abecma Likely to Be Included in June’s AgendaAccess Free BlastFree
Posted in: Autologous, CAR-T May 22 | 2023SC-DARIC33 Shows Promising Preliminary Clinical Results; 2seventy Bio Reveals Next-Generation AML Program; ASGCT 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T May 19 | 2023Ph1 TSCAN-001 Trial Shows Encouraging Preliminary Results; TScan to Initiate Trial in Solid Tumors in 2023; 8 IND Submissions Expected by YE 2024; Kelonia Presents Promising In Vivo CAR-T Preclinical Results; ASCGT 2023 Analysis 1Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.